Remedy Meds Expands Telehealth Reach with $500 Million Acquisition of Thirty Madison

2025-09-05 digitalcare

New York, Friday, 5 September 2025.
Remedy Meds acquires Thirty Madison for over $500 million in an all-stock deal, enhancing its telehealth services across diverse health sectors. The merger aims to improve patient access and service delivery.

Strategic Merger to Enhance Telehealth Services

The acquisition of Thirty Madison by Remedy Meds, valued at over $500 million, marks a significant move in the telehealth sector. This all-stock transaction positions Remedy Meds to expand its offerings beyond its current GLP-1 weight loss medications to include a broader array of health services. The merger is set to create a multi-specialty telehealth platform that combines Remedy Meds’ existing services with Thirty Madison’s portfolio, which includes brands such as Nurx for women’s health, Cove for migraines, and Keeps for men’s hair loss [1][2][3].

Impact on Access and Service Delivery

The merger is expected to improve patient access to specialty care by leveraging the strengths of both companies. Thirty Madison’s established clinical infrastructure, which includes in-house pharmacies and a dedicated medical team, will be integrated with Remedy Meds’ acquisition engine and pharmacy infrastructure. This integration aims to provide more efficient service delivery, including same-day video consultations and direct prescription delivery. The combined entity is predicted to generate over $670 million in annual revenue, with Remedy Meds contributing $450 million and Thirty Madison adding $220 million [1][3][4].

Market Position and Future Prospects

The merger places Remedy Meds and Thirty Madison in a stronger position to compete with established telehealth giants such as Hims and Ro. The deal not only broadens the reach of Remedy Meds’ telehealth services but also strengthens its market position in women’s health, men’s health, and metabolic conditions. Remedy Meds’ CEO, Haris Memon, has indicated that the company is eyeing a potential IPO within the next 12 to 18 months, further underscoring its growth ambitions [1][4][5].

Broader Implications for Healthcare Integration

This acquisition is emblematic of the broader trend in the healthcare industry towards integration and consolidation, aimed at delivering comprehensive and accessible care. By combining resources, the two companies aim to improve health outcomes and efficiency in service delivery. This strategic merger could serve as a model for future partnerships in the telehealth space, emphasizing the importance of scalable platforms and integrated care models in meeting the growing demand for digital health solutions [1][2][5].

Bronnen

telehealth mergers and acquisitions